0001599901-24-000044.txt : 20240315
0001599901-24-000044.hdr.sgml : 20240315
20240315161224
ACCESSION NUMBER: 0001599901-24-000044
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240313
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MacLean Michael F
CENTRAL INDEX KEY: 0001383731
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39321
FILM NUMBER: 24754876
MAIL ADDRESS:
STREET 1: 14 CAMBRIDGE CENTER
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avidity Biosciences, Inc.
CENTRAL INDEX KEY: 0001599901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461336960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-401-7900
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity Biosciences LLC
DATE OF NAME CHANGE: 20161227
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity NanoMedicines LLC
DATE OF NAME CHANGE: 20140211
4
1
wk-form4_1710533514.xml
FORM 4
X0508
4
2024-03-13
0
0001599901
Avidity Biosciences, Inc.
RNA
0001383731
MacLean Michael F
C/O AVIDITY BIOSCIENCES, INC.
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
1
Common Stock
2024-03-13
4
M
0
40000
8.82
A
84093
D
Common Stock
2024-03-13
4
S
0
40000
24.519
D
44093
D
Stock Option (Right to Buy)
8.82
2024-03-13
4
M
0
40000
0
D
2030-05-14
Common Stock
40000
244427
D
Includes the following securities previously acquired by the Reporting Person: (i) 39,384 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.
This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.44 to $24.67. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to the option vested on May 15, 2021, and 1/48th of the original number of shares subject to the option will vest monthly thereafter.
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
2024-01-23